220 related articles for article (PubMed ID: 18316099)
1. Modeling of cancer virotherapy with recombinant measles viruses.
Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
[TBL] [Abstract][Full Text] [Related]
2. Mathematical modeling of cancer radiovirotherapy.
Dingli D; Cascino MD; Josić K; Russell SJ; Bajzer Z
Math Biosci; 2006 Jan; 199(1):55-78. PubMed ID: 16376950
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
[TBL] [Abstract][Full Text] [Related]
4. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
5. In silico evolutionary dynamics of tumour virotherapy.
Reis CL; Pacheco JM; Ennis MK; Dingli D
Integr Biol (Camb); 2010 Jan; 2(1):41-5. PubMed ID: 20473411
[TBL] [Abstract][Full Text] [Related]
6. Optimization of virotherapy for cancer.
Biesecker M; Kimn JH; Lu H; Dingli D; Bajzer Z
Bull Math Biol; 2010 Feb; 72(2):469-89. PubMed ID: 19787406
[TBL] [Abstract][Full Text] [Related]
7. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
8. A multiscale mathematical model for oncolytic virotherapy.
Paiva LR; Binny C; Ferreira SC; Martins ML
Cancer Res; 2009 Feb; 69(3):1205-11. PubMed ID: 19176387
[TBL] [Abstract][Full Text] [Related]
9. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.
Munguia A; Ota T; Miest T; Russell SJ
Gene Ther; 2008 May; 15(10):797-806. PubMed ID: 18356812
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
[TBL] [Abstract][Full Text] [Related]
12. The replicability of oncolytic virus: defining conditions in tumor virotherapy.
Tian JP
Math Biosci Eng; 2011 Jul; 8(3):841-60. PubMed ID: 21675814
[TBL] [Abstract][Full Text] [Related]
13. Use of attenuated paramyxoviruses for cancer therapy.
Lech PJ; Russell SJ
Expert Rev Vaccines; 2010 Nov; 9(11):1275-302. PubMed ID: 21087107
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
[TBL] [Abstract][Full Text] [Related]
16. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
17. Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S; Gao L; Yeagy B; Reid T
Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
[TBL] [Abstract][Full Text] [Related]
18. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
19. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.
Prabhakar S; Messerli SM; Stemmer-Rachamimov AO; Liu TC; Rabkin S; Martuza R; Breakefield XO
Cancer Gene Ther; 2007 May; 14(5):460-7. PubMed ID: 17304235
[TBL] [Abstract][Full Text] [Related]
20. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
